Affimed N.V. - Common Stock (AFMD)

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

Let's have a look at what is happening on the US markets on Friday. Below you can find the most active stocks in today's session.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

The company has been granted an initial period of 180 calendar days, or until October 13, 2025, to regain compliance with Nasdaq’s Minimum Bid Price Rule.

AFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate and significant clinical activity, highlighting potential efficacy of AFM24 with atezolizumab.